Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jun 10, 2021 12:00pm
191 Views
Post# 33362767

RE:What a boring company....

RE:What a boring company....I am about as loyal a TH shareholder as any of us here. But they even managed to finally destroy my faith in them with the OO. It took a concerted effort to get there but they persevered! If I can get to this place, you can imagine how hard it might be for them to convince others to pay attention to their stock at this point. Which is very unfortunate, because their story is actually a very good one and the markerr right now is expecially receptive to such stories. So, it just adds to the epic disaster that the OO was. Hopefully, LSA has a client base that is willing to listen but the low tradng volume tells us they e ither have not really started to present TH to their clients (we probably should not expect much on that front until they have produced a report on TH), LSA does not really have much reach or their clients just are not paying attention to the TH story.    

We had pretty good trading volume earlier in the year as Soleus added to their position acquired in the OO. You can attract some temporary attention to your stock when you give it away at a ridiculously low price. But the market can figure out that if you are so foolish as to do something like the OO, why should they trust you? Since there are many stocks out there, they just move onto companies that do not appear as self-destructive. And the volume dries up.

Despite all of that, the fact still remains that TH has a very intriguing cancer drug that could financially alter all of our lives, despite the fundamental mistakes the company has made in the past, if things go well with the cancer trial. They also have a promising phase III NASH drug in a space where the competition keeps coming up short. They have a very real chance to hit it big in two huge markets and if they only get one to work, that still translates into much. much higher share price in the long run (maybe the short run if cancer works).

And we are a now just little more than a week away from when the company will be telling us something about the cancer opportunity. Chances are it will be positive info but given where they are in the trial, it is not likely to be the definitive positive info we are all hoping to hear later this year. Still, it may cause some new investors, with the assistance of LSA, to take an interest in TH and get the trading volume back up to far less boring levels. 

Bucknelly21 wrote: These guy are just boring as hell. It's no wonder they can't get anyone excited about anything in the pipeline 


<< Previous
Bullboard Posts
Next >>